Trial Profile
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab: A Phase III Randomized Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Carcinoma; Early breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms A-BRAVE; A-BRAVE Trial
- 30 Oct 2023 Planned End Date changed from 1 Jun 2023 to 1 Oct 2025.
- 30 Oct 2023 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2024.
- 31 Mar 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Jun 2022.